Edo Vellenga

University Medical Center Groningen — Netherlands

Medicine · Health Sciences

97h-index39.6kcitations845works4.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(255), Multiple Myeloma Research and Treatments(104), Hematopoietic Stem Cell Transplantation(91), Chronic Myeloid Leukemia Treatments(66), Cytokine Signaling Pathways and Interactions(66)

Publications840 total

Autologous stem cell transplantation versus consolidation chemotherapy as post-remission treatment in newly diagnosed favorable and intermediate risk patients with AML: A comparative analysis of HOVON-SAKK-Nordic trials
Blood·2025Open Access
Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial
Leukemia·2024· 9 citedOpen Access
Clonal hematopoiesis in patients with stem cell mobilization failure: a nested case-control study
Blood Advances·2022· 7 citedOpen Access
Presence of mutant p53 increases stem cell frequency and is associated with reduced binding to classic TP53 binding sites in cell lines and primary AMLs
Experimental Hematology·2022· 4 citedOpen Access
On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs)
Blood·2021· 5 cited
Peripheral blood cytopenias in the aging general population and risk of incident hematological disease and mortality
Blood Advances·2021· 15 citedOpen Access
Low relapse risk in poor risk AML after conditioning with 10-day decitabine, fludarabine and 2 Gray TBI prior to allogeneic hematopoietic cell transplantation
Bone Marrow Transplantation·2021· 10 citedOpen Access
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
Blood Advances·2021· 65 citedOpen Access
Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS
Cancers·2021· 14 citedOpen Access
Daratumumab in transfusion‐dependent patients with low or intermediate‐<scp>1</scp> risk myelodysplastic syndromes
American Journal of Hematology·2021Open Access
Targeted RNA sequencing enables detection of relevant translocations, single nucleotide variants and automatic leukemia classification
Data Archiving and Networked Services (DANS)·2020
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion–Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study
Journal of Clinical Oncology·2020· 122 citedOpen Access
Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
Blood·2020· 8 cited
The IL1-IL1RAP axis plays an important role in the inflammatory leukemic niche that favors acute myeloid leukemia proliferation over normal hematopoiesis
Haematologica·2020· 35 citedOpen Access
Targeted RNA-Sequencing Enables Detection of Relevant Translocations and Single Nucleotide Variants and Provides a Method for Classification of Hematological Malignancies–RANKING
Clinical Chemistry·2020· 10 citedOpen Access
3035 – THE IL1-IL1RAP AXIS PLAYS AN IMPORTANT ROLE IN THE INFLAMMATORY LEUKEMIC NICHE THAT FAVORS ACUTE MYELOID LEUKEMIA CELL PROLIFERATION OVER NORMAL HEMATOPOIESIS
Experimental Hematology·2020· 2 cited
Carfilzomib Combined With Thalidomide and Low‐dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial
HemaSphere·2020· 4 citedOpen Access
Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS
Leukemia·2020Open Access
Use of azacitidine and its safety and efficacy in daily clinical practice in The Netherlands: the OCEAN study
Leukemia & lymphoma/Leukemia and lymphoma·2020Open Access
A real-life cohort study of immunoglobulin light-chain (AL) amyloidosis patients ineligible for autologous stem cell transplantation due to severe cardiac involvement or advanced disease
Amyloid·2020· 5 citedOpen Access
page 1 of 42Next →

Frequent Co-authors

Bob Löwenberg(13), Pieter Sonneveld(10), Gert J. Ossenkoppele(8), Bronno van der Holt(6), Leo F. Verdonck(6), Thomas Pabst(6), Sonja Zweegman(5), Pierre W. Wijermans(5), Harry C. Schouten(5), Augustin Ferrant(5), Johan Maertens(5), Bart J. Biemond(5), Gregor Verhoef(5), Pau Montesinos(5), Juan Bergua(5), Javier de la Serna(5), Miguel Á. Sanz(5), Uta Bertsch(4), Gerard M.J. Bos(4), Henk M. Lokhorst(4)